Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND/AIMS: During the last two decades, hundreds of reports have detailed putative prognostic and predictive biomarkers for colorectal cancer (CRC). However, the majority of these studies have been small and retrospective, reporting results that are highly likely to represent false positives. Consequently, their relevance to clinical practice requires definition. METHODS: Review of published literature on CRC biomarkers, focusing on early-stage disease. RESULTS: Although most putative biomarkers have failed to be validated in subsequent studies, level I evidence now indicates that tumour microsatellite instability can be used to identify a cohort of patients with stage IIA disease at low risk of relapse who can be spared adjuvant chemotherapy. Emerging data suggest that gene expression arrays may have a role in selecting patients with stage IIA disease and mismatch repair-proficient tumours for chemotherapy following tumour resection. CONCLUSION: Despite the profusion of biomarker literature, only mismatch repair status can be recommended as routine in current clinical practice. High-quality, adequately powered studies are essential to accurately define the utility of existing and putative biomarkers, and to support their rational application in the clinic.

Original publication

DOI

10.1159/000341890

Type

Journal article

Journal

Dig Dis

Publication Date

2012

Volume

30 Suppl 2

Pages

27 - 33

Keywords

Biomarkers, Tumor, Chromosomal Instability, Chromosome Deletion, Chromosomes, Human, Pair 18, Colorectal Neoplasms, DNA Mismatch Repair, Gene Expression Profiling, Humans, Microsatellite Instability, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), ras Proteins